Mitochondrial pyruvate carrier

Class

Mitochondrial-target insulin sensitizer

The mitochondrial pyruvate carrier (MPC) is a protein complex embedded in the inner mitochondrial membrane that shuttles pyruvate, the end-product of glycolysis, from the cytosol into the mitochondrial matrix. Once inside, pyruvate feeds into the tricarboxylic acid cycle and oxidative phosphorylation, or is redirected toward fat synthesis and gluconeogenesis depending on the tissue and metabolic state. Because this transport step gates how much carbon flux enters mitochondrial metabolism, it has become a target for addressing metabolic diseases characterized by dysregulated fuel handling, including insulin resistance, type 2 diabetes, and fatty liver disease (particularly its more severe inflammatory and fibrotic form). Partially restricting pyruvate entry can shift cellular metabolism toward fat oxidation, reduce inappropriate glucose production by the liver, and dampen downstream lipid accumulation and inflammatory signaling in liver and other tissues. This mechanism is distinct from earlier insulin-sensitizing drugs that acted primarily through a nuclear receptor called PPAR-gamma; MPC-directed agents were developed to achieve metabolic benefits while minimizing the receptor-driven side effects, such as fluid retention and weight gain, historically associated with that older drug class. The broader rationale is that modulating a single, well-defined metabolic checkpoint may offer more tissue-selective and mechanistically cleaner control over glucose and lipid handling than agents with wider receptor engagement.